Sanofi MenQuadfi wins EU approval for use in infants from six weeks - SNY News | RalliesSanofi MenQuadfi wins EU approval for use in infants from six weeks
S
SNY• EU expands MenQuadfi label
- EU regulators extended the indication for Sanofi’s MenQuadfi vaccine to include infants from six weeks of age.
- The label expansion broadens EU market access beyond the prior authorization for people aged 12 months and older.
- The European Commission decision follows a positive CHMP opinion dated June 25, 2026.
